The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...